A group of statisticians who had argued for rejection were overruled, internal memos show, as high-ranking agency officials got behind an accelerated clearance for Biogen's drug.
Original source: https://www.healthcaredive.com/news/fda-alzheimers-drug-approval-documents-disagreement/602279/